Covered recipient · General Payments record
DENISE A YARDLEY
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$12,075.16
102 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $8,245.60 | 4 |
| Food and Beverage | $2,301.54 | 85 |
| Long term medical supply or device loan | $1,147.29 | 12 |
| Travel and Lodging | $380.73 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $3,066.82 | 4 |
| Genentech USA, Inc. | $2,954.82 | 6 |
| PFIZER INC. | $2,204.23 | 8 |
| Novartis Pharmaceuticals Corporation | $1,914.71 | 19 |
| AstraZeneca Pharmaceuticals LP | $888.57 | 11 |
| Merck Sharp & Dohme LLC | $158.61 | 8 |
| Regeneron Healthcare Solutions, Inc. | $145.48 | 11 |
| Daiichi Sankyo Inc. | $100.16 | 4 |
| Janssen Biotech, Inc. | $82.56 | 4 |
| E.R. Squibb & Sons, L.L.C. | $80.42 | 4 |
| ARRAY BIOPHARMA INC | $55.90 | 3 |
| Eisai Inc. | $46.02 | 2 |
| GlaxoSmithKline, LLC. | $38.22 | 2 |
| PharmaEssentia USA Corporation | $37.11 | 2 |
| Celgene Corporation | $36.08 | 2 |
| RECORDATI_RARE_DISEASES_INC. | $32.68 | 1 |
| Astellas Pharma US Inc | $25.17 | 1 |
| AVYXA PHARMA, LLC | $25.13 | 1 |
| Stemline Therapeutics Inc. | $24.16 | 1 |
| BeOne Medicines USA, Inc. | $23.74 | 1 |
| TAIHO ONCOLOGY, INC. | $23.55 | 1 |
| SpringWorks Therapeutics, Inc. | $22.23 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19.12 | 1 |
| ACCORD HEALTHCARE, INC. | $18.51 | 1 |
| Coherus Oncology, Inc. | $18.50 | 1 |
| Exelixis Inc. | $17.69 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $14.97 | 1 |
Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DENISE A YARDLEY
NPI 1801829114 · CMS profile ID 36050
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NASHVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DENISE A YARDLEY, NPI 1801829114, CMS profile ID 36050. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DENISE A YARDLEY, NPI 1801829114, CMS profile ID 36050. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DENISE A YARDLEY, NPI 1801829114, CMS profile ID 36050, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
102 matching records · $12,075.16 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–102 of 102.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PharmaEssentia USA Corporation | $18.20 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246831637 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.57 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214786539 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,578.94 | 2 |
| PY2025 | Principal investigator | $809,805.84 | 143 |
| PY2024 | Recipient | $8,186.87 | 1 |
| PY2024 | Principal investigator | $335,282.66 | 58 |
| PY2023 | Recipient | $16,456.43 | 6 |
| PY2023 | Principal investigator | $1,184,465.63 | 66 |
| PY2022 | Recipient | $952.00 | 2 |
| PY2022 | Principal investigator | $2,109,619.40 | 67 |
| PY2021 | Recipient | $27,760.00 | 3 |
| PY2021 | Principal investigator | $3,398,665.70 | 75 |
| PY2020 | Recipient | $6,422.00 | 6 |
| PY2020 | Principal investigator | $4,199,414.73 | 184 |
| PY2019 | Recipient | $25,205.79 | 5 |
| PY2019 | Principal investigator | $1,092,374.62 | 226 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
145 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,402.83 | 12/31/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC,The Sarah Cannon Research Institute | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232927163 |
| Principal investigator 1 | Genentech, Inc. | $3,049.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211650039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 12/18/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 12/18/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 12/15/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 12/15/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 12/10/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 12/10/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767819 |
| Principal investigator 1 | Genentech, Inc. | $2,695.00 | 12/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211650036 |
| Principal investigator 1 | Genentech, Inc. | $42.00 | 12/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211650002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,644.00 | 12/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,296.00 | 12/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,774.00 | 12/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,474.00 | 12/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $705.00 | 12/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,775.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,000.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,200.00 | 12/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767821 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211652705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 11/20/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767789 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,500.00 | 11/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185541750 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,200.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192156907 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $19,500.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192156913 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,900.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192156921 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192185265 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192185278 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,900.00 | 11/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192185282 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,151.25 | 11/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192185286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,915.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $108.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,986.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,231.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $355.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,617.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $705.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $705.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $705.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $108.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $371.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $108.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $108.00 | 11/03/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767759 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $81,860.85 | 10/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220998295 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $122,791.28 | 10/31/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220998297 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,749.80 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192156903 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,930.53 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192156918 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 10/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228741772 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,800.00 | 10/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192185269 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,700.00 | 10/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | No dispute reported | 06/30/2026 | 1192185274 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 10/22/2025 | Non-covered Recipient Entity Scri Oncology Partners | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175273191 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228730585 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228730607 |
| Principal investigator 1 | PFIZER INC. | $169.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228741731 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211652384 |
| Principal investigator 1 | Genentech, Inc. | $9,713.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211652421 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,064.05 | 10/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190309512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767755 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211652311 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,645.54 | 09/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190303751 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/02/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767747 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $52,089.13 | 08/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185541748 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211649841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767743 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 07/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228762362 |
| Recipient | Novartis Pharmaceuticals Corporation | $3,395.14 | 07/17/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190292445 |
| Principal investigator 1 | Genentech, Inc. | $10,178.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211652193 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651926 |
| Principal investigator 1 | Genentech, Inc. | $3,067.75 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211649874 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767751 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $526.84 | 07/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190303749 |
| Principal investigator 1 | PFIZER INC. | $1,630.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228778200 |
| Principal investigator 1 | PFIZER INC. | $1,479.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228786747 |
| Principal investigator 1 | PFIZER INC. | $5,200.00 | 06/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228791945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $509.10 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $539.46 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.00 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.66 | 06/24/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767739 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228792884 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 06/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228793190 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 06/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211650899 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $85,176.46 | 06/17/2025 | Non-covered Recipient Entity TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190310168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767725 |
| Principal investigator 1 | Genentech, Inc. | $1,056.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651516 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651563 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,150.00 | 05/28/2025 | Non-covered Recipient Entity Tennessee Oncology, PLLC,The Sarah Cannon Research Institute | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232927119 |
| Principal investigator 1 | PFIZER INC. | $588.00 | 05/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228773590 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,183.80 | 05/13/2025 | Covered Recipient Physician | CLEE011O12301C | No dispute reported | 06/30/2026 | 1190292441 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/13/2025 | Non-covered Recipient Entity Tennessee OncologyNashvilleSarah Cannon Research Institute | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228754976 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 05/13/2025 | Non-covered Recipient Entity Tennessee OncologyNashvilleSarah Cannon Research Institute | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228758068 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/12/2025 | Non-covered Recipient Entity Tennessee OncologyNashvilleSarah Cannon Research Institute | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228757695 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 05/12/2025 | Non-covered Recipient Entity Tennessee OncologyNashvilleSarah Cannon Research Institute | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228758028 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 05/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228782356 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 05/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228782461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767721 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 04/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175274309 |
| Principal investigator 1 | Genentech, Inc. | $8,682.00 | 04/23/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651127 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 04/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651077 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 04/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651045 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 04/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211651190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767717 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $600.00 | 03/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in | No dispute reported | 06/30/2026 | 1190304449 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 03/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228783757 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 03/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211650352 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 03/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211650502 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 03/07/2025 | Non-covered Recipient Entity Scri Oncology Partners | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175274496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767701 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 02/26/2025 | Non-covered Recipient Entity Scri Oncology Partners | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175274528 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $475.16 | 02/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $319.68 | 02/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 02/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $122.14 | 02/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $82.00 | 02/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.12 | 02/25/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767713 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.90 | 02/12/2025 | Non-covered Recipient Entity Scri Oncology Partners | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175273353 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 02/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228796219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 01/30/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767689 |
| Principal investigator 1 | Genentech, Inc. | $6,346.00 | 01/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211650634 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,250.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3- | No dispute reported | 06/30/2026 | 1190304457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 01/14/2025 | Non-covered Recipient Entity Scri Oncology Partners | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175274146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 01/13/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767687 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $48,841.75 | 01/09/2025 | Non-covered Recipient Entity TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190310170 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228799043 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 01/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228801265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Scri Oncology Partners | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220767693 |